- Approval Id
- 1a70849146325945
- Drug Name
- DIFFLAM LOZENGE 3 mg
- Product Name
- DIFFLAM LOZENGE 3 mg
- Approval Number
- SIN07411P
- Approval Date
- 1993-04-29
- Registrant
- INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
- Licence Holder
- INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
- Drug Type
- Therapeutic
- Forensic Classification
- Pharmacy Only
- Dosage Form
- LOZENGE
- Dosage
- **DOSAGE AND ADMINISTRATION**
Difflam Anti-inflammatory Lozenges should not be chewed. They should be slowly dissolved in the mouth. One lozenge should be sucked slowly every one to two hours as required up to a maximum of 12 lozenges per day. Uninterrupted treatment should not exceed seven days.
**With Impaired Renal Function**
Since absorbed benzydamine and its metabolites are excreted in the urine, the possibility of systemic effects should be considered in patients with severe renal impairment.
**With Impaired Liver Function**
Since absorbed benzydamine is highly metabolised in the liver the possibility of systemic effects should be considered in patients with severe hepatic impairment.
- Route Of Administration
- ORAL
- Indication Info
- **INDICATIONS**
For the temporary relief of painful conditions of the oral cavity including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, post-orosurgical and periodontal procedures, pharyngitis, swelling, redness and inflammatory conditions.
- Contraindications
- **CONTRAINDICATIONS**
Patients with known hypersensitivity to benzydamine or to any of the components of the vehicle.
- Atc Code
- A01AD02
- Atc Item Name
- benzydamine
- Pharma Manufacturer Name
- INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED
- Company Detail Path
- /organization/inova-pharmaceuticals-singapore-pte-limited
